![Some doctors insist on brand-name drugs even when cheaper generics are available - The Washington Post Some doctors insist on brand-name drugs even when cheaper generics are available - The Washington Post](https://www.washingtonpost.com/rf/image_1484w/2010-2019/WashingtonPost/2011/07/07/Health-Environment-Science/Advance/Images/advice12b.jpg?t=20170517)
Some doctors insist on brand-name drugs even when cheaper generics are available - The Washington Post
![Value-Based Pricing of Prescription Drugs Benefits Patients and Promotes Innovation - Center for American Progress Value-Based Pricing of Prescription Drugs Benefits Patients and Promotes Innovation - Center for American Progress](https://www.americanprogress.org/wp-content/uploads/2021/09/ValueBasedDrugPricing.jpg?w=1040)
Value-Based Pricing of Prescription Drugs Benefits Patients and Promotes Innovation - Center for American Progress
![Bye-bye, blockbuster? AstraZeneca's Faslodex gets U.S. generic on heels of record sales year | Fierce Pharma Bye-bye, blockbuster? AstraZeneca's Faslodex gets U.S. generic on heels of record sales year | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1559310272/AstraZeneca%20Faslodex%20package.jpg/AstraZeneca%20Faslodex%20package.jpg?VersionId=bTLCc3179_20TldkDpXTtNIFvcyasvUu)
Bye-bye, blockbuster? AstraZeneca's Faslodex gets U.S. generic on heels of record sales year | Fierce Pharma
![Reforms Are Needed To Rein In Health Spending, But Reference Pricing Isn't Worth The Risk | Health Affairs Reforms Are Needed To Rein In Health Spending, But Reference Pricing Isn't Worth The Risk | Health Affairs](https://www.healthaffairs.org/do/10.1377/forefront.20211004.561448/full/health-affairs-blog-referencepricing-pharmaceuticals-buelt.png)
Reforms Are Needed To Rein In Health Spending, But Reference Pricing Isn't Worth The Risk | Health Affairs
![Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/asset/b2c0fa87-783e-431b-9875-88b62f1d30c9/gr1.jpg)
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology
![Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study | Scientific Reports Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-62318-y/MediaObjects/41598_2020_62318_Fig2_HTML.png)